| Autor: |
Hamed, Gehane M., Nassef, Noha A., Eissa, Rania S. A., Shawky, Mona K. E., Abo Zeid, Asmaa A., Hassan, Arwa A. |
| Předmět: |
|
| Zdroj: |
QJM: An International Journal of Medicine; 2021 Supplement, Vol. 114, pi316-i316, 1p |
| Abstrakt: |
Background: Osteoporosis is a common bone disease and is associated with considerable morbidity and mortality. Osteoporosis occurs most frequently in postmenopausal women. The inadequacy of current treatments and their side effects have driven a search for improved methods of dealing with osteoporosis. Design: Experimental study. Aim of Work: This study was conducted to throw light on the ability of BM-MSCs and/or PRP in improving bone formation and slow down bone loss in ovariectomized rats with osteoporosis. Materials & Methods: This study was carried out on adult female Wistar rats allocated randomly into five groups: Shamoperated, OVX untreated, OVX-MSCs treated (MSCs administered once intravenously), OVX/PRP treated (PRP administered once subcutaneously), OVX-MSCs/PRP treated groups. Rats were subjected to assessment of serum ALK, CTX-1, MDA and TNF-a. In addition, specimens of tibia were taken and processed for light microscopic studies and morphometric analysis. Results: OVX untreated group showed significant increases in serum levels of ALK and CTX-1. Significant elevations of serum MDA and TNF-a levels were also noticed in the OVX untreated group. Administration of BM-MSCs and PRP significantly lowered serum levels of ALK, CTX-1, MDA and TNF-a. These results were confirmed by the histopathological findings. Conclusion: BM-MSCs together with PRP can partially reverse OVX-induced bone loss and halt osteoporosis progression. Abbreviations: BM-MSCs: bone marrow derived mesenchymal stem cells, PRP: platelet-rich plasma, OVX: ovariectomized, ALK: alkaline phosphatase, CTX-1: cross linked c telopeptide of type 1 collagen, MDA: malondialdehyde, TNF-a: tumour necrosis factor-alpha. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
